BMJ Open

MUFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trial

Jean Philippe Galanaud 1, Jameel Abdulrehman 2, A Lazo-Langner 3, Grégoire Le Gal 4, Sudeep Shivakumar 5, Sam Schulman 6, Susan Kahn 7

ABSTRACT

Introduction After deep vein thrombosis, up to 50% of patients develop post-thrombotic syndrome (PTS). PTS is a chronic condition that reduces quality of life (QOL). Cornerstones of PTS treatment include the use of elastic compression stockings but this treatment is usually incompletely effective and is burdensome. Venoactive drugs have been reported to be effective to treat chronic venous insufficiency (CVI). However, the level of evidence supporting their use in CVI in general and in PTS in particular is low.

Methods and analysis The MUFIN-PTS trial is an academic, publically funded, multicentre randomised placebo-controlled trial assessing the efficacy of micronised purified flavonoid fraction (MPFF, Venixxa), a venoactive drug, to treat PTS. Eighty-six patients with PTS (Villalta score (VS) ≥5) and experiencing at least two of the following PTS manifestations among daily leg heaviness, cramps, pain or oedema will be randomised to receive 1000 mg of oral MPFF or a similar appearing placebo for 6 months, in addition to their usual PTS treatment. Total study follow-up will be 9 months, with visits at inclusion/baseline, 3, 6 and 9 months. Primary outcome is the proportion of patients with improvement in VS in each group, where improvement is defined as a decrease of at least 30% in VS or a VS <5 in the PTS-affected leg. Main secondary outcomes include QOL and patient satisfaction.

Ethics and dissemination Primary ethics approval was received from Centre intégré universitaire de santé et de services sociaux (CIUSSS) West-Central Montreal Research Ethics Board. Results of the study will be disseminated via peer-reviewed publications and presentations at scientific conferences.

Trial registration number ClinicalTrials.gov Registry (NCT03833024); Pre-results.

INTRODUCTION

The post-thrombotic syndrome (PTS) refers to the clinical manifestations of chronic venous insufficiency (CVI) that occur after a deep vein thrombosis (DVT). PTS is the most frequent complication of DVT. Despite treatment of DVT with anticoagulants, PTS occurs in up to 50% of patients after proximal DVT, and 5%–10% of patients with DVT develop severe PTS.

While not life-threatening, PTS constitutes an important health problem as it reduces quality of life (QOL) and is associated with increased costs and health resource utilisation. The current cornerstone of PTS treatment is the use of elastic compression stockings (ECS). However, ECS are often not fully effective as judged by clinicians and not perceived to be effective in about one-third of patients. More importantly, use of ECS is burdensome as they must be worn each day from morning to evening, which limits compliance to ECS and, ultimately, ECS effectiveness.

Thus, there is a pressing need for new therapeutic targets for the treatment of PTS. Venoactive drugs or phlebotonics which comprise a heterogeneous group of medicinal products of plant or synthetic origin could constitute an attractive option. They are simple-to-use oral medications, seem to be well tolerated and are potentially better pathophysiologically
targeted than ECS (Li et al, Micronized purified flavonoid fraction for the treatment of chronic venous insufficiency, with a focus on post-thrombotic syndrome: A narrative review (under review)). Venoactive drugs have shown some effectiveness in patients with CVI and are suggested as a second option, after ECS failure, to treat swelling and pain related to CVI in the latest European Society of Vascular Surgery guidelines (grade IIa). However, venoactive drugs have not been definitively evaluated for the treatment of PTS and their effectiveness in this indication is unknown. Thus, international guidelines on the management of venous thromboembolic (VTE) disease currently do not recommend venoactive drugs have not been definitively evaluated for the treatment of PTS and their effectiveness in this indication is unknown. Thus, international guidelines on the management of venous thromboembolic (VTE) disease currently do not recommend

METHODS AND ANALYSIS

The Micronized Purified Flavonoid Fraction (MPFF) for the Treatment of Post-Thrombotic Syndrome trial (MUFFIN-PTS) is a double-blind multicentre RCT assessing the efficacy of a 6-month course of MPFF versus placebo in patients with PTS.

The venoactive drug used in this trial is MPFF (commercialised under the name of Venixxa in Canada and Daflon/Venarus in some other countries). MPFF contains 90% micronised diosmin and 10% of flavonoids expressed as hesperidin. The micronisation of the drug to particles with a diameter ≤2 µm improves MPFF oral absorption, shortens its onset of action and potentially improves its efficacy in relieving symptoms and signs of CVI. Studies and literature reviews suggest that MPFF is effective to treat CVI and might be effective to treat PTS and is safe.

Objectives of the trial

The primary objective of the MUFFIN-PTS trial is to assess whether a 6-month course of 500 mg two times per day of MPFF (Venixxa) improves PTS as compared with a placebo drug.

Secondary objectives are to assess:

► If MPFF improves PTS severity as compared with placebo.
► If MPFF improves each individual component of the Villalta score (VS) as compared with placebo.
► If MPFF improves venous disease-specific QOL and generic QOL as compared with placebo.
► If MPFF improves patient satisfaction with treatment as compared with placebo.
► Patient compliance with treatment.
► Serious adverse events (SAEs) including drug-related SAE, DVT, pulmonary embolism (PE) and death.
► If MPFF is cost-effective. This will be assessed only if MPFF is found to be superior to placebo in the primary outcome analysis.

Description of trial procedures

This study is being conducted in seven Canadian centres. The clinical trial coordinating centre is located in Montreal (Lady Davis Institute, Jewish General Hospital). Co-principal investigators are Drs Jean-Philippe Galanaud and Susan R Kahn. All investigators are members of the Canadian Institute of Health Research (CIHR)-funded CanVECTOR research network. Patients with PTS (VS ≥5), as per International Society on Thrombosis Haemostasis (ISTH) guidance for PTS diagnosis, and at least two of the following daily PTS manifestations (leg heaviness, cramps, pain, oedema) will be potentially eligible to participate. The study inclusion and exclusion criteria as well as timeline and procedures are summarised in figure 1. Eligible and consenting participants will be randomised to receive either MPFF (Venixxa) 500 mg oral or oral placebo capsules identical in appearance to MPFF, 1 capsule two times per day (morning and evening) for 6 months. Placebo will be manufactured by Bay Area Research Logistics (Hamilton, Ontario, Canada), a Health Canada-approved company, and will look identical to MPFF/Venixxa capsules. Study drugs will be packaged in identical plain boxes, labelled with a unique code for that participant (ie, patients and study personnel blinded). Randomisation will be done online via a web-based system (Information Management Services (IMS), Montreal, Quebec, Canada). Patients will be allowed to continue all other previous treatments for PTS, except venoactive drugs (which are very rarely used in Canada).

This includes the use of ECS, exercise training and lifestyle measures (eg, leg elevation, avoiding a sedentary lifestyle, avoiding prolonged exposure to heat, maintaining a non-obese body weight and using moisturising creams to avoid skin breakdown). Standard treatment of PTS (ECS, exercise training, lifestyle changes, or rarely, interventional radiological procedures for severe PTS) is expected to be similar at all study sites across Canada and is expected to be balanced between groups. Information on ECS use, strength and compliance will be documented at baseline and each follow-up visit as ECS could impact assessment of our primary outcome.

Study participants will be followed for 9 months after enrolment. They will have scheduled clinical assessments at baseline (day 0: day of enrolment), 3, 6 and 9 months (±14 days). The objective of the 9-month follow-up visit is to assess if any between-group differences noted at 6 months have changed by 3 months after the end of study drug treatment.

Unscheduled assessments will take place if patients have symptoms suggestive of a SAE. Details of study procedure for each follow-up visit are presented in table 1. If a patient is unable to attend any of the follow-up visits in person, a telephone follow-up visit will be scheduled to assess PTS using the validated patient-reported Villalta scale. However, in-person attendance at all follow-up visits will be strongly encouraged. In the event a patient
Patients with PTS (VS ≥ 5 and previous DVT or RVO on US in ipsilateral leg) and ≥ 2 of the following manifestations in the affected leg: daily heaviness, cramps, pain or edema

- Recent acute ipsilateral DVT (<3 months)
- Active ipsilateral venous ulcer
- Acute or chronic altered mental status
- Liver cirrhosis Child-Pugh class C
- Alcohol/drug abuse
- End-stage kidney disease (dialysis, creat cl <10 ml/min)
- Any venaevent drug intake < 3 months before study start
- Allergy or hypersensitivity to MPFF

Exclude if

Excluded patients

R

Eligible and Consenting patients

MPFF, 1 capsule of 500mg BID

Placebo, 1 capsule BID

F/U Visit 1 (± 14 days): PTS, QOL, compliance, satisfaction, SAE

F/U Visit 2 (± 14 days): PTS, QOL, compliance, satisfaction, SAE, unblinding

F/U Visit 3 (± 14 days): PTS, QOL, SAE

Primary outcome: Proportions of patients with improvement in VS in each group at 6 months

Secondary outcomes: PTS improvement (M3,M9), PTS severity (M3, M6, M9), Each individual component of VS (M3, M6, M9), Venous disease specific and generic QOL scores (M3, M6, M9), Patient overall satisfaction with tnt (M3, M6), SAE (B to M6) , patient compliance with tnt (M3, M6), SAE (B-M6, M6-M9)

Figure 1 MUFFIN-PTS flow diagram. B, baseline; BID, two times per day; creat cl, creatinine clearance; DVT, deep vein thrombosis; F/U, follow-up; M3, 3-month F/U visit; M6, 6-month F/U visit; M9, 9-month F/U visit; MPFF, micronised purified flavonoid fraction; PTS, post-thrombotic syndrome; QOL, quality of life; RVO, residual venous obstruction; SAE, serious adverse event; US, ultrasound; VS, Villalta score.

Table 1 MUFFIN-PTS trial: procedures undertaken at each follow-up visit

| Visit | 1 | 2 | 3 | 4 |
|-------|---|---|---|---|
| Timing | | | | |
| Informed consent | X | | | |
| Randomisation | X | | | |
| Baseline CRF | X | | | |
| F/U form | | | | |
| Concomitant medications | X | X | X | X |
| Bilateral Villalta score and PTS assessment | X | X | X | X |
| QOL | X | X | X | X |
| Patient’s overall satisfaction with treatment | | X | X | X |
| Compliance to study treatment | | | | |
| Assessment of unblinding | | | | |
| SAE: VTE recurrence, death, drug-related SAE | To be completed anytime SAE is suspected | | | |
| Withdrawal | To be completed whenever a patient withdraws from the study | | | |

CRF, case report form; F/U, follow-up; PTS, post-thrombotic syndrome; QOL, quality of life; SAE, serious adverse event; VTE, venous thromboembolism.
Assessment of outcomes

Primary outcome

Improvement of PTS at 6 months. As recommended by the ISTH, PTS will be assessed with the Villalta scale in the DVT-affected leg. In the case of bilateral PTS, we will use the leg with the highest Villalta score at inclusion for assessment of efficacy of MPFF; for patients with unilateral PTS and a VS ≥5 in the leg contralateral to DVT (ie, non-PTS-related venous insufficiency), we will use the DVT-affected leg for assessment of study drug efficacy. Improvement will be defined by: absence of PTS at the 6-month visit (VS <5 in the PTS-affected leg) or, in patients who still have PTS, a decrease of at least 30% in the VS between baseline and 6-month assessments. Improvement (reduction) in VS rather than complete resolution of symptoms and signs of PTS was chosen to assess the efficacy of MPFF because (1) some patients may have persistent/irreversible symptoms and signs of PTS such as hyperpigmentation or lipodermatosclerosis which can prevent them from ever having a VS <5 during study follow-up; and (2) given the current absence of effective treatments for PTS, even incomplete relief of symptoms and signs is desirable.

Secondary outcomes

- Severity of PTS at 3, 6 and 9 months will be assessed (1) based on the validated Villalta scale severity categories, namely: mild, VS 5–9; moderate, 10–14; and severe, >14 or presence of ulcer; and (2) based on the VS (continuous variable).
- QOL at 3, 6 and 9 months: will be measured using validated generic (EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire) and venous disease-specific (VEINES-QOL) measures.
- Patient’s overall satisfaction with treatment at 3 and 6 months will be evaluated with a 5-point Likert visual analogue scale (1=very satisfied to 5=very unsatisfied).
- Patient’s compliance to study drug treatment will be measured by review of the medication diary and pill count that patients will complete daily and bring to the 3-month and 6-month follow-up visits. Compliance will be considered satisfactory if at least 80% of the study drug was reportedly taken and unsatisfied). Patient compliance to allocated treatment in secondary exploratory analyses, but not for sample size adjustment.
- SAEs will be defined using the Health Canada definition and reported as required by local regulations.
- Suspected recurrent DVT or PE will be confirmed by objective tests using criteria recommended by the ISTH.
- Success of blinding will be evaluated by asking patients, investigators and research nurses at 6 months or at the end of each patient’s participation, if earlier than 6 months, which treatment they believe they received, and the level of confidence of their responses.

Sample size and power calculations

In a recent meta-analysis of published RCTs, Kakkos and Nicolaides reported that Venixxa (Daflon), as compared with placebo, reduced the severity of leg pain, cramps and paresthesia by about 50% (relative risk (RR)=0.53, p=0.0001; RR=0.51, p=0.02; and RR=0.45, p=0.03, respectively) and leg heaviness by 65% (RR=0.35, p<0.00001). In Gilly et al’s and Cospite and Dominici’s RCTs, Venixxa (Daflon) was shown to reduce the intensity of symptoms and signs of CVI by at least threefold and in Chassignolle et al’s trial, by at least twofold. About 55% of patients on MPFF stated being very satisfied with treatment, suggesting clinically relevant improvement, as compared with only 10% of patients in the placebo group. Based on the above, we hypothesise that at least 50% of patients randomised to the Venixxa group will achieve the primary endpoint (ie, VS <5 or reduction in VS ≥30%). We anticipate that 20% of patients will have some PTS improvement due to a placebo effect, supported by data which suggest that on average, there could be at most a 50% mean reduction in symptoms intensity with placebo. A total sample size of 86 patients (accounting for a conservative 10% rate of death/loss to follow-up) has 80% power to show an absolute 30% risk reduction in the primary outcome, that is, from 20% of patients improved in the placebo group to 50% of patients improved in the MPFF group, number needed to treat (NNT)=4 with a two-tailed α of 0.05. We will examine the impact of patient compliance to allocated treatment in secondary explanatory analyses, but not for sample size adjustment.

Statistical analyses

We will use an intention-to-treat approach for all outcomes. For the primary outcome, improvement in PTS at 6 months, a X² test will be performed, stratified by centre. Tests will be two-sided with α level set at 0.05. The NNT for benefit will be calculated. In secondary analyses, we will explore the role of pre-randomisation variables (centre, duration of anticoagulation treatment and type of anticoagulation for index DVT, characteristics of index DVT: proximal vs distal; provoked vs unprovoked; bilateral vs unilateral; cancer vs non-cancer associated; and presence of contralateral vs no contralateral CVI), and post-randomisation variables (use of ECS, compliance with study drug, recurrent ipsilateral DVT during follow-up) that could influence clinical change in PTS, using logistic regression with multiple imputation to account for missing values, if necessary. In addition, adjustment for selected baseline PTS risk factors including age, sex and body mass index will be explored if there is evidence of clinically relevant differences in these variables between the two treatment groups.

For the secondary outcomes PTS severity (categorical), PTS VS (continuous), individual components (ie, symptoms, signs) of the VS, occurrence of venous leg...
ulcer, venous disease-specific and generic QOL, patient compliance with treatment, patients’ overall satisfaction with treatment, SAEs such as drug-related SAE, recurrent VTE and death, rates in the two intervention groups will be described, and between-group differences explored with similar procedures. For differences in mean QOL scores between groups, analysis of covariance will adjust for baseline score. Score differences on the order of 3–4 points will be considered clinically important. With 43 patients per group including a 10% dropout rate, we will have greater than 90% power to detect a 3-point difference in VEINES-QOL, assuming an SD of 9 (expected SD based on our prior work). A secondary explanatory (per-protocol) analysis will be conducted using similar procedures.

Data management
Data management will be overseen by IMS. Data will be entered online at study sites by the study nurse using a customised web-based data entry tool using validation checks at the time of data entry. Data will be reviewed and cleaned by the database coordinator on an ongoing basis by initiating and following up on queries to the sites. The cleaned database, blinded to treatment assignment, will be provided to the biostatistician for analysis, which will be carried out under the supervision of the study investigators.

Patient and public involvement
A patient partner who is a member of the Patient Partners platform of the CanVECTOR research network (www.canvector.ca) was involved in the design of this study, will participate as a member of the study steering committee and will be involved in knowledge dissemination activities after study completion.

Ethics and dissemination
The MUFFIN-PTS trial is funded by a grant from the CIHR (#332593). The study protocol was approved by Biomedical Research Ethics Committee of Centre intégré universitaire de santé et de services sociaux (CIUSSS) West-Central Montreal Research Ethics Board on 29 June 2020 (Project 2019-1656). Written informed consent will be obtained from all participating patients and consent form is provided as an online supplemental file. The MUFFIN-PTS trial is expected to begin enrolling patients in 2021. Results of the study will be disseminated via peer-reviewed publications and presentations at scientific conferences. Open access to individual patient data is not planned, but all requests for the trial’s data will be considered on an individual basis by the trial steering committee.

DISCUSSION
Given the absence of simple and effective methods to treat patients with PTS and as PTS can markedly reduce patients’ QOL, it is critical to evaluate new treatment options for patients with PTS. One option could be the use of venoactive drugs that are commonly used in Europe to treat CVI.

However, several considerations must be kept in mind before suggesting the use of these drugs for PTS. First, although several guidelines suggest or recommend the use of venoactive drugs to treat CVI, the quality of evidence suggesting their effectiveness is not high. In their last updated Cochrane meta-analysis focusing on venoactive drugs in patients with CVI, Martinez-Zapata et al concluded that low-to-moderate certainty evidence suggests that venoactive drugs probably reduce oedema and might, or might not, improve QOL. The authors underlined the need for additional high-quality RCTs focusing on clinically important outcomes. Second, the pathophysiology of PTS comprises several mechanisms, including residual venous obstruction, valvular reflux and acute DVT-related inflammation, each involved to varying degrees, depending on the individual patient’s DVT. The pathophysiology of PTS appears to be more complex than the pathophysiology of ‘standard’ primary chronic venous insufficiency (comprises venous reflux and some degree of inflammation). Thus, it is conceivable that treatment efficacy for a given treatment might differ between PTS and CVI, and hence results of CVI treatment studies should not be extrapolated to patients with PTS. It is therefore critical to conduct a RCT of venoactive drug specifically in patients with PTS.

We chose to test MPFF as the venoactive drug intervention for the following reasons: the literature suggests that compared with other venoactive drugs (eg, horse chestnut seed extract, ruscus extract, calcium dobesilate), MPFF—and rutosides—appear to be the most effective and safest venoactive drugs for the treatment of signs (oedema, skin changes) and symptoms related to CVI. Importantly, MPFF is the venoactive drug that has the most wide-ranging mechanisms of action for the treatment of CVI, including unique anti-inflammatory properties that are directly relevant to PTS pathophysiology. Furthermore, a recent Cochrane meta-analysis found no evidence that rutosides were superior to ECS or to placebo to treat PTS. In contrast, data on MPFF in patients with PTS are scarce but encouraging: two studies have assessed the clinical effectiveness of MPFF and both of them reported some improvement in PTS symptoms. However, these studies were small or retrospective, published in Russian language and neither was an RCT. While two small older double-blind RCTs assessed the effectiveness of MPFF (Daflon) in PTS, they did not assess clinical endpoints and rather assessed changes in venous tone, capacity and outflow. The MPFF dose that we will use (1000 mg daily) in the MUFFIN-PTS trial is the most widely used dose in published studies. A 1000 mg once daily formulation was shown to be equivalent to 500 mg two times per day, but this dose strength is not available in Canada.

Regarding study design, given the high risk of a placebo effect in PTS studies, we opted for a double-blind design. Our sample size could be perceived as

Galanaud JP, et al. BMJ Open 2021;11:e049557. doi:10.1136/bmjopen-2021-049557
modest. However, based on our careful literature review, we hypothesise that there will be a 50% improvement in the primary study outcome in the MPFF arm, compared with placebo. Considering the cost of MPFF and the non-life-threatening character of PTS, we do not believe that MPFF should be used if its efficacy is only marginal. We are aware that treatment duration (6 months) might be perceived as too short to adequately assess treatment for a chronic disease. However, our 6-month treatment duration is in line with experts’ recommendations that future trials of CVI treatment should include treatment periods of at least 3 months.20 Further, studies showed that the beneficial effect of MPFF may be noticed as early as 2 weeks after MPFF initiation, that the benefit increased with time and that the greatest improvements in QOL and PTS/CVI symptoms were achieved when patients were treated for at least 3 months.22 47–52 Our 6-month duration of treatment will be longer than the previous longest treatment duration (4 months) in an RCT of MPFF to treat CVI in patients without venous ulcers.20 21 If MPFF is shown to be effective to treat PTS without side effects or adverse events, longer duration of treatment will likely be needed and ideally tested.

In conclusion, the MUFFIN-PTS trial will provide definitive data on the benefits of MPFF to treat PTS. Its results should be highly relevant for patients and healthcare providers and could impact daily clinical management of patients with PTS. Indeed, providing strong evidence in support of the effectiveness and tolerability of MPFF may convince physicians to routinely prescribe MPFF to their patients with PTS, and will improve the health and QOL of patients with PTS. From the patient’s perspective, given the health burden and impaired QOL caused by PTS, a non-invasive and safe treatment to reduce the burden of PTS is desirable. From a healthcare perspective, given the high costs of treating PTS, an intervention that reduces PTS severity could be cost-effective and even cost-saving. Conversely, if no benefit of MPFF to treat is shown, many thousands of PTS patients each year around the world could be spared the cost and inconvenience of taking ineffective medications.

Author affiliations
1 Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
2 Medicine, University Health Network, Toronto, Ontario, Canada
3 Medicine, Western University, London, Ontario, Canada
4 Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
5 Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
6 Medicine, McMaster University, Hamilton, Ontario, Canada
7 Medicine, McGill University, Montreal, Quebec, Canada

Acknowledgements
SK is a Tier 1 Canada Research Chair holder. All investigators are members of the CanVECTOR Network, which receives grant funding from the Canadian Institutes of Health Research (Funding Reference: CDT-142654).

Contributors
JPG and SK wrote the protocol, designed the study and wrote the article. JA, AL-L, GLG, SSH and SSC revised and approved the protocol, critically revised and approved the article.

Funding
This work is supported by a grant from the Canadian Institute of Health Research (SK foundation grant number: 332593).

REFERENCES
1 Rabinovich A, Kahn SR. How I treat the postthrombotic syndrome. Blood 2018;131:2215–22.
2 Makedonov I, Kahn SR, Galanaud J-P. Prevention and management of the post-thrombotic syndrome. J Clin Med 2020;9:923.
3 Galanaud J-P, Monreal M, Kahn SR. Epidemiology of the post-thrombotic syndrome. Thromb Res 2018;164:1-9.
4 Prandoni P. Healthcare burden associated with the post-thrombotic syndrome and potential impact of the new oral anticoagulants. Eur J Haematol 2012;88:185–94.
5 Kahn SR, Galanaud J-P, Verlantsham S, et al. Guidance for the prevention and treatment of the post-thrombotic syndrome. J Thromb Thrombolysis 2016;41:144–53.
6 Kolbach DN, Sandbrink MWC, Neumann HAM, et al. Compression therapy for treating stage I and II (Widmer) post-thrombotic syndrome. Cochrane Database Syst Rev 2003;CD004177.
7 Cohen JM, Aki EA, Kahn SR. Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials. Chest 2012;141:308–20.
8 Lim CS, Davies AH. Graduated compression stockings. CMAJ 2014;186:E391–8.
9 Raju S, Hollis K, Neglen P. Use of compression stockings in chronic venous disease: patient compliance and efficacy. Ann Vasc Surg 2007;21:790–5.
10 Galanaud J-P, Bertoletti L, Amitrano M, et al. Predictors of post-thrombotic ulcer after acute DVT: the RITIE registry. Thromb Haemost 2018;118:320–8.
11 Palacios FS, Rathbun SW. Medical treatment for Postthrombotic syndrome. Semin Intervent Radiol 2017;34:61–7.
12 Kearon C, Aki EA, Omelas J, et al. Antithrombotic therapy for VTE disease: chest guideline and expert panel report. Chest 2016;149:315–52.
13 ten Cate-Hoeck AJ, Weitz JL, Gallani D, et al. Theme 3: non-invasive management of (recurrent) venous thromboembolism (VTE) and post-thrombotic syndrome (PTS). Thromb Res 2015;136 Suppl 1:S13–18.
14 Martinez-Zapata MJ, Verrooij RWM, Uirona Tuma SM, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev 2016;4:CD003329.
15 Witters C, Davies AH, Bakgaard N, et al. Editor’s Choice - Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2015;49:678–737.
16 Kahn SR, Comerota AJ, Cushman M, et al. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American heart association. Circulation 2014;130:1636–61.
17 Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids. Drugs 2003;63:71–100.
18 Boukelska E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular
permeability induced by various agents and on ischemia/reperfusion in the hamster cheek pouch. *Angiology* 1997;48:391–9.

19 Garner RC, Garner JV, Gregory S, et al. Comparison of the absorption of micronized (Daflon 500 Mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerometer mass spectrometry and liquid scintillation counting. *J Pharm Sci* 2002:91:32–40.

20 Kakko SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. *Int Angiol* 2018;37:143–54.

21 Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients with subacute chronic venous disease: from a prospective randomized trial. *Int Angiol* 2015;34:428–36.

22 Son’kin IN, Shaidakov EV, Krylov DV, et al. [Efficacy of Venaros in treatment of patients with post-thrombotic disease of lower limbs]. *Angiol Sosud Khir* 2014;20:77–83.

23 Tsukanov YT, Tsukanov AV, Levandisky EG. Secondary varicoses small pelvic veins and their treatment with micronized purified flavonoid fraction. *Int J Angiol* 2016;25:121–7.

24 Kahn SR, Partsch H, Vedantham S, et al. Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. *J Thromb Haemost* 2009;7:879–83.

25 Utne KK, Ghanima W, Foyn S, et al. Development and validation of a tool for patient reporting of symptoms and signs of the post-thrombotic syndrome. *J Thromb Haemost* 2016;11:361–7.

26 Prandoni P. Elastic stockings, hydroxyethylrutosides or both for the treatment of post-thrombotic syndrome. *Thromb Haemost* 2005;93:183–5.

27 Lamping DL, Schrotter S, Kurz X, et al. Evaluation of outcomes in chronic venous disease of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. *J Vasc Surg* 2003;37:410–9.

28 Kahn SR, Lamping DL, Ducruet T, et al. VEINES-QOL/Sym questionnaire was a reliable and valid disease-specific quality of life measure for deep venous thrombosis. *J Clin Epidemiol* 2006;59:1056.e1–1056.e4.

29 Vuotilaenen A, Pitkäaho T, Kvist T, et al. How to ask about patient satisfaction? the visual analogue scale is less vulnerable to confounding factors and ceiling effect than a symmetric Likert scale. *J Adv Nurs* 2016;72:946–57.

30 Overview of the Reporting Adverse Reactions to Marketed Health Products - Guidance Document for Industry. Available: https://www.canada.ca/en/health-canada/services/drugs-health-products/products-guidance-document-industry.html

31 Ageno W, Squizzato A, Wells PS, et al. The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTH. *J Thromb Haemost* 2013;11:1597–602.

32 Cospietà M, Dominici A. Double blind study of the pharmacodynamic and clinical activities of 5682 se in venous insufficiency, advantages of the new micronized form. *Int Angiol* 1989;8:61–5.

33 Gilly R, Pillion G, Frileux C. Evaluation of a new venoactive micronized flavonoid fraction (S 5682) in symptomatic disturbances of the venolymphatic circulation of the lower limb: a double-blind, placebo-controlled study. *Phlebology* 1994;9:67–70.

34 Chassignolle J-F, Amiel L, Lanfranchi G. Activité thérapeutique de Daflon 500 mg dans l’insuffisance veineuse fonctionnelle. *J Int Med* 1987;99:32–7.

35 Kahn SR, Shapiro S, Wells PS, et al. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. *Lancet* 2011;383:880–8.

36 Plantadit S. Chapter 7. Clinical trials: a methodological perspective. New York: John Wiley and Sons, 1997.

37 Ware JE KM, Keller S. SF-36 physical and mental summary measures: A user's manual. Boston: The Health Institute, New England Medical Center, 1994.

38 Ware JE SK, Kosinski MA, Gandek B. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center, 1994.

39 Rabe E, Guey J-J, Morrison N, et al. Treatment of chronic venous disease with flavonoids: recommendations for treatment and further studies. *Phlebology* 2013;28:308–19.

40 Nicolaides A, Kakko S, Eklot B, et al. Management of chronic venous disorders of the lower limbs - guidelines according to scientific evidence. *Int Angiol* 2014;33:97–208.

41 Martinez-Zapata MJ, Vernoool RW, Simancas-Racines D, et al. Phlebotonics for venous insufficiency. *Cochrane Database Syst Rev* 2020;11:CD003229.

42 Pitsch F. The place of Daflon 500 Mg in recent international guidelines on the management of symptomatic chronic venous disorders. *Medicographia* 2011;33:306–18.

43 Rabinovich A, Cohen JM, Cushman M, et al. Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome. *J Thromb Haemost* 2015;13:398–408.

44 Morling JR, Broderick C, Yeoh SE, et al. Rutosides for treatment of post-thrombotic syndrome. *Cochrane Database Syst Rev* 2018;11:CD005625.

45 Amiel MBR. Etude du délai et de la durée d’action de Daflon 500 mg*. *Int Angiol* 1989;2:32–9.

46 Tsouderos Y. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? our experience with Daflon 500 Mg. *Int Angiol* 1989;2:32–9.

47 Kiriseno A, Radak D. Clinical acceptability study of once-daily versus twice-daily micronized purified flavonoid fraction in patients with symptomatic chronic venous disease: a randomized controlled trial. *Int Angiol* 2016;35:399–405.

48 Carpenter P, van Bellen B, Karetova D, et al. Clinical efficacy and safety of a new 1000-mg suspension versus twice-daily 500-mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial. *Int Angiol* 2017;36:402–9.

49 Galanaud JP, Genty-Vernorel C, Rolland C, et al. Compression stockings to prevent postthrombotic syndrome: literature overview and presentation of the CELEST trial. *Res Pract Thromb Haemost* 2020;4:1239–50.

50 Navratilova Z. Efficacy of a 6-month treatment with Daflon 500 mg* in patients with venous edema (efficacy of Daflon 500 mg* in edema treatment EDET). *Phlebology* 2010;17:137–42.

51 Lenkov M, Zgombic ZS, Blazic TM. Benefit of Daflon 500 Mg in the reduction of chronic venous disease-related symptoms. *Phlebology* 2012;19:79–83.

52 Yanushko V, SS BAA. Benefits of MPFF on primary chronic venous disease-related symptoms and quality of life: the delta study. *Phlebology* 2014;21:146–51.